STUDY OF THE PROBLEM OF LATENT TUBERCULOSIS INFECTION IN HIV-INFECTED INDIVIDUALS
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrak:
Latent tuberculosis infection (LTBI) remains one of the most significant challenges in global tuberculosis (TB) control, particularly among people living with HIV (PLHIV). HIV infection dramatically increases the risk of reactivation of latent Mycobacterium tuberculosis infection, contributing to high morbidity and mortality rates worldwide. This article presents a comprehensive review and analytical assessment of the epidemiology, immunopathogenesis, diagnostic challenges, preventive therapy, and public health implications of LTBI in HIV-infected individuals. Special attention is given to immunological mechanisms underlying reactivation, limitations of tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs) in immunocompromised populations, and current WHO recommendations for tuberculosis preventive therapy (TPT). The study highlights the urgent need for improved diagnostic tools, integrated TB-HIV programs, and personalized preventive approaches to reduce TB incidence among PLHIV. Strengthening LTBI screening and preventive treatment strategies remains critical to achieving global TB elimination goals
##plugins.themes.bootstrap3.article.details##
##submission.howToCite##:
##submission.citations##:
World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva; 2020.
Getahun H, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372:2127–2135.
Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009;4:325–333.
Gupta RK, et al. Isoniazid preventive therapy in HIV-infected individuals. Lancet Infect Dis. 2016;16:119–130.
Rangaka MX, et al. Predictive value of interferon-gamma release assays. Lancet Infect Dis. 2012;12:45–55.
Sterling TR, et al. Three months of rifapentine and isoniazid for LTBI. N Engl J Med. 2011;365:2155–2166.
Churchyard GJ, et al. Tuberculosis preventive therapy for HIV-infected persons. Clin Infect Dis. 2014;59:S112–S120.
Esmail H, et al. The immune response to tuberculosis in HIV. Semin Immunol. 2014;26:437–444.
UNAIDS. Global HIV & AIDS statistics — 2023 fact sheet.
Getahun H, et al. Implementation of isoniazid preventive therapy. AIDS. 2010;24:S1–S10.
Gupta A, et al. Tuberculosis incidence among HIV-infected individuals. Clin Infect Dis. 2012;54:162–169
Fitzgerald DW, Severe P, Joseph P, Mellon LR, Noel E, Johnson WD, Pape JW. No effect of isoniazid prophylaxis for purified protein derivative‐negative HIV infected adults living in a country endemic tuberculosis: results of a randomized trial. Journal of Acquuired Immune Deficiency Syndromes 2001;28(3):305‐307.
Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, Klein M, Vaughn A, Besch CL, Perez G, Szabo S, El‐Sadr W. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. NEJM 1997;337:315‐320.
Halsey NE, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geitre L, Johnson E, Huebner R, Boulos R, Chaisson R. Randomized trial of isoniazid versus rifampicine and pyrazinamide for prevention of tuberculosis in HIV‐1 infection. The Lancet 1998;351(9105):786‐792.
Hawken MP, Meme HK, Elliot LC, Chakaya JM, Morris JS, Githui WA, Juma ES, Odhiambo JA, Thiong'o LN, Kimari JN, Ngugi EN, Bwayo JJ, Gilks CF, Plummer FA, Porter JDH, Nunn PP, McAdam KPWJ. Isoniazid preventive therapy for tuberculosis in HIV‐1 infected adults: results of a randomized controlled trial. AIDS 1997;11:875‐882.
Martinez AEM, Cuadra F, Solera J, Macia MA, Geijo P, Sanchez MPA, Rodriguez ZM, Largo J, Sepilveda MA, Rosa C, Sanchez L, Espinosa A, Mateos F, Blanch JJ. Evaluation of 2 tuberculosis chemoprohylaxis regimens in patients infected with human immunodeficiency virus. The Gecmei Group. Medicina Clinica (Barcelona) 2000;115(5):161‐165.
aenghirunvattana S. [Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV‐infected individuals]. J. Med Association Thai 1996;79(5):285‐287.
Akileswaran C, Lurie NM, Flanigan TP, Mayer KH. Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa. Clinical Infectious Disease 2005;41(3):376‐385.
Badri M, Wilson D, Wood RE. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359(9323):2059‐64.